Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Cognitive Dysfunction in Schizophrenia
Date:12/8/2008

WILMINGTON, Del. and WINSTON-SALEM, N.C., Dec. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and Targacept, Inc. today announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

AZD3480 did not meet the trial's criteria for statistical significance on the primary endpoints, improvement on various cognitive domains measured by the IntegNeuro computerized test battery. AZD3480 was generally well tolerated in the study. AstraZeneca and Targacept do not expect to progress AZD3480 into Phase III studies for CDS.

In addition to the HALO trial, AstraZeneca and Targacept previously announced top-line results from a Phase IIb study of AZD3480 in mild to moderate Alzheimer's disease, known as the Sirocco trial, and are currently evaluating AZD3480 in a Phase II exploratory study in attention deficit/hyperactivity disorder (ADHD) in adults. A decision by AstraZeneca with respect to potential further development of AZD3480 in Alzheimer's disease or ADHD is now expected in the first half of 2009, pending completion of the adult ADHD study and other ongoing evaluations.

"While this trial outcome did not meet our objectives, we continue to pursue medicines that target neuronal nicotinic receptors (NNRs) with Targacept to treat cognitive disorders," said Bob Holland, Vice President and Head of the Neuroscience Therapy Area, AstraZeneca.

Targacept and AstraZeneca also announced that the lead compound arising out of the parties' preclinical research collaboration is poised to enter the clinic. AstraZeneca plans by the end of 2008 to initiate a Phase I trial of AZD1446 (TC-6683), a product candidate selective for the alpha4beta2 NNR. Under the terms of the parties' collaborat
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA
2. AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimers Disease
3. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
4. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
5. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
6. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
7. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
10. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
11. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... LONDON , Sept. 1, 2014 ... Brazil Aesthetic Lasers and Energy ... https://www.reportbuyer.com/product/2343455/Brazil-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Brazil Aesthetic ... Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:9/1/2014)... Sept. 1, 2014 ... is available in its catalogue: Antibody ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... new class of therapeutic agents, gaining increasing attention ... addressed as the marriage of an antibody with ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... is available in its catalogue:  Drug Discovery ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The ... such as cancer requires extensive expenditure, in addition ... step in designing a new drug involves the ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... 10, 2010 /PRNewswire-FirstCall/ -- HealthWarehouse.com, Inc ... leading VIPPS accredited retail mail-order pharmacy, announced today that ... equity and convertible debt with independent investors. ... company,s online presence while upgrading its technology infrastructure to ...
... 10, 2010 Nycomed US Inc. announced today the ... Vice President and General Counsel, reporting to Steve Andrzejewski, ... legal advisor of the company and oversee all of ... he will also be responsible for the company,s compliance ...
Cached Medicine Technology:HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 2HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 3Joseph J. LaRosa Joins Nycomed US Inc. 2
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
(Date:9/1/2014)... 01, 2014 As well as having ... is currently pursuing counselor certification in Louisiana. ... the CPI training program as well as the ... grown both personally and professionally. I am not ... competently able to do so. As a Non ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 BCC Research ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the ... million in 2013 and is expected to reach $38.7 ... to $471.5 million by 2019, which is equivalent to ... 2019. The receptor-mediated transport (RMT) segment is forecasted to ...
(Date:9/1/2014)... In honor of National Take Your Cat to the Vet Day, ... of Minnesota (AERC) is offering a few reasons why pet owners ... people don’t take their cat to the vet because “there’s nothing ... decide not to take their kid to dentist because he or ... pets. Just like people want their loved ones to be healthy, ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... A 29-year-old Indonesian man has died of bird flu, bringing ... to 80, the world's highest, an official said Friday. ... in hospital Tuesday in Pekanbaru, capital of Riau province on ... at the Indonesian health ministry. ,"He had a ...
... been transferred back to the LA prison where she is ... medical ward. ,Jail authorities said that the hotel ... Towers Correctional Facility for less than a week. ... jail sentence for violating terms of probation, was taken to ...
... getting some extra sleep before a big game could ... ,Researcher Cheri Mah and colleagues at Stanford University observed ... ,They were told to maintain their usual sleeping habits ... they were instructed to get as much extra sleep ...
... over the legislation aimed at preventing discrimination of the HIV ... ,Union Health Minister Anbumani Ramadoss said that the HIV/AIDS bill ... with the NGOs on the issue that could guarantee safe-working ... ,The bill also provides for access to treatment ...
... identified by Yale School of Medicine researcher Michael Kozal, ... quickly detects rare viral mutations. ,Kozal, associate ... the retrospective study that used samples from an earlier ... International HIV Drug Resistance Workshop in Barbados. ...
... thought a toilet could save her so much time and money. ... shack in Kibera, Africa's largest slum, she realized it could. ... installed the latrine that uses human waste to produce gas to ... dwellers. ,"At first I thought it was a very ...
Cached Medicine News:Health News:Bill on HIV/AIDS Delayed Further 2Health News:HIV Drug Resistance can Be Identified by Genome Sequencing 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 3
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: